key: cord-1011854-l1uxodb2
authors: Acosta-Ampudia, Yeny; Monsalve, Diana M.; Rojas, Manuel; Rodríguez, Yhojan; Gallo, Juan Esteban; Salazar-Uribe, Juan Carlos; Santander, María José; Cala, Mónica P.; Zapata, Wildeman; Zapata, María Isabel; Manrique, Rubén; Pardo-Oviedo, Juan Mauricio; Camacho, Bernardo; Ramírez-Santana, Carolina; Anaya, Juan-Manuel
title: COVID-19 convalescent plasma composition and immunological effects in severe patients
date: 2021-01-22
journal: J Autoimmun
DOI: 10.1016/j.jaut.2021.102598
sha: 3d15b8ccf9424e102c2f1dac03908f854f44ae7e
doc_id: 1011854
cord_uid: l1uxodb2

Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = <0.0001), IL-10 (P = <0.0001), IP-10 (P = <0.0001), fatty acyls and glycerophospholipids were higher than in recovered patients. Latent autoimmunity and anti–IFN–α antibodies were observed in both recovered and severe patients. COVID-19 CP induced an early but transient cytokine profile modification and increases IgG anti-S1-SARS-CoV-2 antibodies. At day 28 post-transfusion, a decrease in activated, effector and effector memory CD4(+) (P < 0.05) and activated and effector CD8(+) (P < 0.01) T cells and naïve B cells (P = 0.001), and an increase in non-classical memory B cells (P=<0.0001) and central memory CD4(+) T cells (P = 0.0252) were observed. Moreover, IL-6/IFN-γ (P = 0.0089) and IL-6/IL-10 (P = 0.0180) ratios decreased in plasma recipients compared to those who received standard therapy alone. These results may have therapeutic implications and justify further post-COVID-19 studies.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 , has infected over 89 million people around the world (https://coronavirus.jhu.edu/map.html) becoming a serious public health threat. Although most people with COVID-19 are asymptomatic or have mild disease, about 20% may present with severe illness [1, 2] .

Preventive and treatment options for COVID-19 remain under study. Therefore, traditional interventions have re-emerged as a new therapeutic alternative. CP has been used for decades for the prevention or treatment of infectious diseases when no specific treatment was available [3] . CP can provide passive immunity by transfusion of neutralizing antibodies (NAbs) and other immune components from patients who have recovered from an infection, to unexposed or infected individuals in order to reduce the risk of disease or to lessen its clinical impact [4] . This strategy has been used for the treatment of several viral infections, including Spanish influenza, parvovirus B19, H1N1, Ebola and other coronaviruses.

However, conclusive data from randomized and controlled trials are lacking [5] [6] [7] [8] .

Passive immunization with plasma from recovered COVID-19 patients to SARS-CoV-2 infected patients could help to control the infection before patients have generated a proper immune response [4] . The Food and Drug Administration (FDA) authorized the use of CP in COVID-19 patients as an investigational new drug for the treatment of this disease [9] . Up to date, several studies have published some promising benefits [10] [11] [12] [13] . The early administration of CP J o u r n a l P r e -p r o o f 9 containing high IgG antibody titers against SARS-CoV-2 may not only decrease disease severity, but may also decrease mortality [14] . However, due to a high methodological variability in selection criteria for donors and recipients, dosage, NAbs concentration, disease severity, outcomes, among others, it is difficult to objectively assess the real therapeutic potential of CP [15] .

COVID-19 is characterized by an overzealous activation of the innate and adaptive immune system leading to hyper-inflammation that are primarily a result of high levels of pro-inflammatory cytokines and cell dysregulation [16] . In this regard, transfusion of CP to infected patients may provide antibodies, cytokines, and other active factors that may modulate the immune response against SARS-CoV-2, thus attenuating the severe inflammatory response [3] . The main mechanism of action of CP involves, among others, the presence of NAbs against SARS-CoV-2 protein S, which are correlated with total IgG and IgA antibody levels [17] . Since its entire mechanisms of action are not fully understood, we aimed to evaluate the composition of the CP in terms of SARS-CoV-2 antibodies, autoantibodies, cytokines and metabolites, as well as its effect on the immune response in patients with severe COVID-19, up to 28 days after treatment.

This was a two-phase controlled study in which, first CP composition and the basal immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, its longitudinal effect at 28-day follow-up period on the immune response in severe patients was determined (Fig. 1A ) (see section 2.7). J o u r n a l P r e -p r o o f 10 

The institutional review board at the Universidad del Rosario approved the study design. Written informed consent was obtained from all study participants.

Participants were recruited from the following three medical centers: (1) Clínica del Occidente; (2) Clínica CES; and (3) Hospital Universitario Mayor Méderi in Colombia. Participants were recruited from July 1, 2020 to August 25, 2020. Follow-up was completed on September 22, 2020. Patients were selected using non-probabilistic sampling (i.e., convenience selection). Plasma recipients were selected from the CP pilot study (NCT04332380), whereas patients who received exclusively standard therapy were selected from a randomized controlled trial (NCT04332835). The latter group comprised the first nine consecutive controls who were included in that study. Consecutive inclusion of plasma donors was also performed.

Participants were divided into three groups, as follows: pre-pandemic control group (n= 16); patients who recovered from SARS-CoV-2 infection (n= 19) , which included super-donors (n= 11) and donors (n= 8) on the basis of their antibody titers (see below); and patients who were hospitalized with severe COVID-19 (n= 18) , whom after day 0 were split into two groups: plasma recipient (n= 9) and standard therapy (n= 9).

J o u r n a l P r e -p r o o f 11 Pre-donation process included the following steps/criteria: (1) signed informed consent; (2) aged between 18 and 65 years; (3) subjects with a laboratoryconfirmed COVID-19 diagnosis by reverse transcriptase-polymerase chain reaction (RT-PCR) having been hospitalized but not at the intensive care unit (ICU), discharged and recovered between 14 and 30 days before the pre-donation assessment; (4) two consecutive negative RT-PCR results from nasopharyngeal swabs within 48 hours before donation; (5) women were only accepted if they did not have pregnancy history or a current suspicion of pregnancy; (6) negativity for HIV, hepatitis B and C virus, HTLV 1 and 2, syphilis, and Trypanosoma cruzi infection. Potential donors were screened for IgG and IgA antibodies, and classified as super-donors and donors according to antibody levels. Subjects with IgG antibody titers ≥1:3200 and IgA antibody titers ≥1:800 to SARS-CoV-2 were considered super-donors and were chosen for plasmapheresis and further therapeutic transfusion. Subjects who did not reach those titers were considered as donors, and were discard for plasmapheresis, but its serum composition was analyzed in this study. Approximately, 800 mL of plasma were collected from super-donors. Prior freezing, pathogens inactivation with Riboflavin followed by UV light exposure was performed [18] .

Inclusion criteria were the following: (1) signed informed consent; (2) were not included.

Exclusion criteria included the following: (1) pregnancy or breast feeding; (2) patients with prior allergic reactions to transfusions; (3) critically ill patients in ICU;

(4) patients with surgical procedures in the last 30 days; (5) subjects with active treatment for cancer (i.e., radiotherapy or chemotherapy); (6) diagnosis of HIV in subjects with viral failure (i.e., detectable viral load > 1000 copies/ml), two consecutive viral load measurements within a 3-month interval; (7) subjects with other confirmed infection that explains clinical manifestations; (8) end-stage kidney disease (i.e., glomerular filtration rate <15 ml/min/1.73 m2); (9) Child Pugh C stage liver cirrhosis; (10) high cardiac output diseases; (11) autoimmune diseases or immunoglobulin A nephropathy; (12) and subjects not willing to participate.

Each transfusion dose of CP was 250 mL, patients received two doses for a total of 500 mL within 48 hours after study inclusion. Each CP unit was kept separate from other super-donors' units. The transfused CP ABO type was compatible with the J o u r n a l P r e -p r o o f 13 recipient's ABO type in 8 out of 10 transfused patients. Each recipient received CP units from the same super-donor. CP transfusion was administered at 3 mL/min with close monitoring for the first 30 min, and regular monitoring over the following 6 hours.

Standard treatment consisted of symptomatic control and supportive care for COVID-19. This treatment was based upon recommendations from the Colombian Association of Infectology and institutional protocols, which included management with antibiotics, corticosteroids, oxygen, and anticoagulants [19] . Both plasma recipient and standard therapy groups received this treatment.

Sociodemographic and pathological factors were evaluated on day 0. The biological baseline included cytokines, lymphocyte populations, IgA and IgG antibodies for SARS-CoV-2, viral load, blood gases, laboratory surrogate of possible thrombotic process (i.e., D-Dimer), hematological, inflammatory, hepatic and renal parameters. These measurements were repeated on days 4, 7, 14 and 28. In addition, the SOFA scale and the 4C mortality score (i.e., score for prediction of mortality 28 days after hospitalization) were evaluated on admission [20] . The viral load was measured using the Ampliphi ® RT-qPCR SARS-CoV-2 Viral Load Kit (www.ampliphi.co).

The Euroimmun anti-SARS-CoV-2 ELISA (Euroimmun, Luebeck, Germany) was used for serological detection of human IgG and IgA antibodies against the SARS-CoV-2 S1 structural protein, in accordance with the manufacturer's instructions.

The ratio interpretation was <0.8 = negative, ≥0.8 to <1.1 = borderline, ≥ 1.1 = positive [17, 21, 22] . Antibody titration was performed using serial dilutions of serum samples from 1:100 to 1:1,638,400.

Detection of IgM rheumatoid factor (RF), IgG anti-cyclic citrullinated peptide thirdgeneration (CCP3), IgM and IgG anti-cardiolipin antibodies (ACAs), IgM and IgG anti-β2glycoprotein (β2GPI) antibodies, IgG anti-double-stranded DNA (dsDNA) antibodies, IgG anti-thyroglobulin (Tg) antibodies and anti-thyroid peroxidase (TPO) antibodies were quantified by ELISA as previously reported [23] . In addition, anti-nuclear antibodies were detected by IMTEC-ANA-LIA Maxx (Human Diagnostics Magdeburg, Germany) [24] . Assessment of anti-IFN-α antibodies was J o u r n a l P r e -p r o o f 15 done by ELISA (Thermo Fisher Scientific, Waltham, MA) following manufacturer's specifications.

A plaque reduction neutralization test (PRNT 50 ) for SARS-CoV-2 was performed using Vero cells [17] , with serum samples diluted from 1:16 to 1:4,096.

Concentration of 20 human cytokines IL-2, IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-17A, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein-1 (MCP-1), IFN-α, IFN-γ, tumor necrosis factor (TNF)-α, and interferon-γ induced protein 10 (IP-10) in serum samples from patients were assessed using the Cytometric Bead Array (BD Biosciences™, Franklin Lakes, New Jersey, U.S.) in a FACSCanto II™ flow cytometer (BD Biosciences™) [25] .

To increase the metabolite coverage, serum samples were analyzed using an 

For a detailed analysis of the cell phenotype, peripheral blood mononuclear cells were stained with fluorescent antibodies. A minimum of 100,000 lymphocytes per sample were acquired on a FACSCanto II™ flow cytometer (BD Biosciences™). Table 1 ) were analyzed with FlowJo software version 9 (BD Biosciences™).

Briefly, in the univariate analysis, categorical variables were analyzed using frequencies, and quantitative continuous variables were expressed as the mean and standard deviation (SD) or the median and interquartile range (IQR). The Mann-Whitney U-test, the chi-squared or Fisher exact tests were used based on the results. Correlations among variables of interest were performed using the Spearman correlation test, and when necessary, corrected for multiple inference using Holm's method. Generalized linear mixed models (GLMMs) that were adjusted for age and sex were used to evaluate intergroup differences between pre-pandemic controls, donors, super-donors, and COVID-19 patients. Additionally, GLMMs were used to evaluate longitudinal changes in antibody ratios, cytokine delta, and lymphocyte population delta. A P value of <0.05 was set as significant.

Analyses were performed using SAS Studio© (SAS® University Edition, Cary, North Carolina, U.S.) and R version 4.0.1.

To establish the differential biological composition of CP from recovered COVID-19

patients, we compared the plasma of the following groups: samples collected prior (Table 1 ). In patients transfused with CP containing autoantibodies including anti-IFN-α neither adverse events nor mortality was observed. On the other hand, two recipients positive for antibodies anti-IFN-α prior to transfusion deceased.

Next, a panel of 20 cytokines was evaluated. This is of interest since transfusion of pro-inflammatory or anti-inflammatory mediators could influence the recipient response. Cytokines were gathered using principal-component analysis (PCA) ( Fig. 1C ). This analysis revealed, that the only difference between donors and super-donors relied on anti-SARS-CoV-2 S1 levels. Thus, since both donors and super-donors disclosed a similar cytokine profile, it was appropriate to combine the data of these two groups as a unique recovered group for subsequent analyses. P=<0.0001) levels were higher in COVID-19 than in recovered patients (Fig. 1E ).

Although IL-4, IL-8, TNF-α and IFN-γ z-score was slightly increased in recovered patients ( Fig. 1D ), no differences were found at the statistical level.

Non-targeted metabolomic and lipidomic profile was evaluated to assess additional levels and therefore were gathered again as a single recovered group for all subsequent OPLS-DA models.

For recovered and pre-pandemic controls, 50 metabolites were found to be statistically significant (Supplementary Table 2 ). The heatmaps showed that the proportion of most statistically significant metabolite levels were lower in recovered patients, which corresponds to fatty acyls and glycerophospholipids (Fig. 2E ).

When the COVID-19 group was compared with the pre-pandemic control and J o u r n a l P r e -p r o o f 20 recovered groups (Supplementary Table 3 ), the largest class of differential metabolites corresponded to a dysregulation in fatty acids, glycerophospholipids, and glycerolipids, and in a lower proportion of sterol lipids and sphingolipids ( Fig.   2F ). However, the phenotype of recovered patients did not return to a similar phenotype of pre-pandemic controls, and it was characterized by continued altered levels of unsaturated fatty acids, such as arachidonic and linoleic acid (Fig. 2 ).

After the evaluation of CP composition, we aimed to evaluate the immune response in hospitalized patients with COVID-19. Inter-group analysis revealed that plasma recipients and standard therapy patients were similar in age, sex, WHO scale, SOFA score, 4C score, PaO2-FiO2, and viral load on inclusion. In addition, comorbidities and body mass index were similar between groups.

Patients who underwent plasma transfusion received CP within the first 72 hours after hospitalization. None of the patients presented adverse reactions nor acute exacerbation of the disease after CP transfusion (Table 2) .

To characterize the T-and B-cell signature in COVID-19 patients' prior transfusion, a cellular analysis was performed before plasma or standard therapy treatment.

PCA of 30 cell subsets clearly distinguished between COVID-19 patients and prepandemic controls (Fig. 3A) 3B ).

A correlation matrix among clinical and biological parameters was constructed ( Table 4 ).

J o u r n a l P r e -p r o o f 22 Prior longitudinal analysis, a baseline analysis (i.e., Day 0) between the plasma receptor group (i.e., recipients) and the standard therapy group looking for cytokines and immune cell signature was performed. Since this analysis revealed differences for some cell populations (Supplementary Table 5 ) and cytokines (Supplementary Table 6 ), we conducted a longitudinal analysis [delta (∆) changes] to evaluate the effect of CP.

Based on the results of the previous section, we evaluated the immune response induced by CP through longitudinal follow-up in patients with COVID-19 after treatment with CP or standard therapy. No significant differences in clinical outcomes or viral load were found between groups during the follow-up (Fig. 4A , Table 2 ). However, the IgG anti-S1-SARS-CoV-2 ratio value was higher on day 4

in the plasma recipient group ( Table 7) .

For cellular sub-phenotypes, most of the between-group differences were observed at ∆D14 to D28. Plasma recipients showed a positive ∆change in central memory 

Our study showed an ongoing and dynamic immune response differential between treatments. Although antibody-independent mechanisms of action have been proposed to explain the effect of CP [3] , no difference between donors and superdonors in terms of cytokines and metabolomic profile was observed. Super-donors had NAbs titers ≥1:256, which exceeded the FDA recommendation of ≥1:160 [9, 29] . Thus, the main difference between super-donors and donors was in their antibody levels, which highly correlated with NAbs [17] .

J o u r n a l P r e -p r o o f 24 We found a differential metabolomic profile of recovered COVID-19 patients compared with pre-pandemic controls and severe COVID-19 patients. Consistent with previous reports, ours confirmed that COVID-19 patients are characterized by lipid dysregulation in fatty acids, glycerophospholipids, glycerolipids, and sphingolipids, which has been associated with dyslipidemia and oxidative stress [30, 31] . Recovered patients regulated the most prominent metabolic perturbations that were associated with SARS-CoV-2 infection on metabolic function, such as a decrease in lipid levels, along with an increase in ketone bodies. However, the phenotype of recovered patients did not return to a similar phenotype of prepandemic controls, and it was characterized by continued altered levels of unsaturated fatty acids, such as arachidonic and linoleic acid.

COVID-19 patients disclose latent rheumatologic, thyroid and antiphospholipid autoimmunity (Table 1 ) [32] . Several emerging reports have shown that SARS-CoV-2 can lead to autoimmune and auto-inflammatory diseases [33] [34] [35] . The pathogenic mechanisms shared between these diseases suggest that SARS-CoV-2 could act as a triggering factor for the development of autoimmune phenomena in susceptible individuals [16, 36] . Post-COVID-19 long-term studies are warranted to determine whether this latent autoimmunity persists and may evolve towards overt autoimmunity (i.e., clinical disease) [37] . Furthermore, anti-IFN-α antibodies were confirmed in COVID-19 patients. A recent study, showed that some infected individuals with SARS-CoV-2, mainly men produce autoantibodies against IFN-α due to inborn errors of type I IFN immunity [38] . These autoantibodies are J o u r n a l P r e -p r o o f 25 associated with high risk of developing life-threatening pneumonia [39] . However, in this small study, clinical worsening following CP transfusion containing such antibodies was not observed, suggesting that allogenic antibodies anti-IFN-α do not influence clinical outcomes.

We observed that transfusion of CP with high NAbs titers did not significantly modify viral load kinetics. Although early administration of CP to hospitalized COVID-19 patients could reduce severity and mortality [14] , this phenomenon is not exclusively attributable to viral load reduction. Severe COVID-19 patients exhibit a higher viral shedding in a variety of tissues for 20-40 days after onset of disease than mildly ill patients, indicating that severity of illness influences viral load kinetics [40] . All together, data indicate that the level of antibodies does not guarantee viral clearance.

Patients with COVID-19 showed a correlation between hematological and clinical parameters and pro-inflammatory cytokines, as previously reported for SARS-CoV-2 infection [41] [42] [43] [44] . COVID-19 patients showed a hyper-inflammatory response that was characterized by high levels of IP-10, GM-CSF, G-CSF, MCP-1, IFN-α, IL-6, IL-7, IL-8, and IL-10 (Fig. 5) . Accumulating evidence indicate that the severity of COVID-19 is associated with an increased level of inflammatory mediators including the cytokines and chemokines mentioned above [45] [46] [47] . Among these cytokines, IL-6 is one of the key factors associated with lethal complications of COVID-19 patients [48] . IL-6 amplifier is activated by coactivation of nuclear factor (NF)-κB and STAT3, which are potential regulators of the COVID-19-mediated J o u r n a l P r e -p r o o f 26 cytokine storm [47] . High IFN-α levels were observed in COVID-19 patients, as previously shown [46] . However, opposite results for IFN-α have been published [38, 39, 49] . Cytokines release in COVID-19 is influenced by disease duration and severity, sex, age, genetic background including ancestry, and autoimmune phenomena [38, 39, 50] .

High levels of IL-6 and IL-10 can directly block the expansion of lymphoid progenitors [48, 51] , causing lymphopenia. The hyper-inflammatory state (i.e., cytokine storm syndrome) drives the exhaustion of T cell subsets, characterized by perpetuated activation of CD4+ and CD8+ T cells [52] [53] [54] [55] . IL-6 also induces Th17

and Th22 differentiation and favors inflammation [56] .

The inflammatory profile of cytokines in COVID-19 differed from that of recovered patients. CP transfusion early regulates the inflammatory balance among the cytokines evaluated in this study, which have been associated with COVID-19 severity [57] . An increase in IL-8 was observed in recovered patients compared to pre-pandemic controls. Similar results were reported by Hähnel et al., [58] who observed a slight increase in IL-8 in plasma donors, indicating that some proinflammatory cytokines may still be present in the plasma of recovered COVID-19

patients.

CP decreased the IL-6/IL-10 and IL-6/IFN-γ ratios on day 28 post-transfusion.

Recent reports have shown that an increase in the IL-6/IL-10 ratio is related to a poor prognosis in COVID-19 [59] . IL-10 is an immunoregulatory cytokine that can J o u r n a l P r e -p r o o f 27 attenuate inflammatory responses through its Th2 activity and by blocking NF-κB, which negatively regulates IL-6 production [60, 61] . However, a large amount of IL-10 inhibits immune cell function and proliferation, which delays viral clearance and can consequently cause lung damage [62] . The decrease in the IL-6/IFN-γ ratio in the plasma recipient group indicates another mechanism of action of CP. Lagunas-Rangel et al., [63] showed that an increase in this ratio could be associated with COVID-19 severity. Interaction between these two cytokines contributes to the recruitment and adequate elimination of neutrophils which favors the timely resolution of the infection and prompt transition between innate and adaptive immunity [64, 65] . Moreover, CP induced an early but transient increase of TNF-α, IL-8, IL-17A, GM-CSF, and IFN-γ, although the latter was persistently increased at day 28. The understanding of the inflammatory profiles in COVID-19 have demonstrated a dual role of IFN-γ. Some have shown increased IFN-γ in severe COVID-19 patients [66] , while others have shown opposite results [67] . Our results indicated that CP induces a temporary increase in inflammatory cytokines (e.g., IFN-γ and TNF-α) that counteracts the infection by controlling the cytokine storm syndrome, as observed in the decrease in the IL-6/IL-10 and IL-6/IFN-γ ratios.

Our findings also demonstrate that the use of CP attenuates the exhausted phenotype observed in patients before transfusion, since CP decreases activated and effector CD4+ and CD8+ T cells (Fig. 5) . Kalfaoglu et al., [68] [69] found that SARS-CoV-2-specific memory lymphocytes have antiviral function: memory T cells produce cytokines and expand upon antigen re-encounter, while memory B cells express receptors capable of neutralizing the virus. Previous reports have shown that recovery is associated with the increase of T cell memory as suggested by the lack of central memory in severe COVID-19 patients [70] . Likewise, the frequency of memory B cells is a critical indicator of the resolution of the disease in SARS-CoV-2 [71] . CP induces a robust CD4+ and CD8+ T cell response, along with a memory T and B phenotype that could provide long-term immunity.

Our study has several strengths. We included patients in the first 72 hours of admission, and in the first 14 days after symptoms onset, which allowed to limitation of the present study is that the observed results might be from chance alone or the moderate sample size. However, this is unlikely because of the highly significant results that were seen after adjustments and corrections as well as their consistent direction and magnitude within the different analyses.

Total IgG and IgA anti-S1-SARS-CoV-2 antibodies are key factors for CP selection and correlate with NAbs. Serum from recovered patients discloses a different cytokine and metabolite composition than that from patients with severe disease. Anti-SARS-CoV-2 S1 IgA (Titers) B.

Anti-SARS-CoV-2 S1 IgG (Ratio) 

Clinical Characteristics of Coronavirus Disease 2019 in China

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain., Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases

Convalescent plasma in Covid-19: Possible mechanisms of action

How should we use convalescent plasma therapies for COVID-19?

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Convalescent plasma: new evidence for an old therapeutic tool?

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Use of convalescent plasma therapy in SARS patients in Hong Kong

Recommendations for Investigational COVID-19 Convalescent Plasma

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Convalescent Plasma in 5,000 Patients., medRxiv : The Preprint Server for Health Sciences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality

Why will it never be known if convalescent plasma is effective for COVID-19

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma

Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud

Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays

Autoimmune thyroid disease in Colombian patients with systemic lupus erythematosus

Antinuclear autoantibodies: discordance among four different assays

Cytokine and autoantibody clusters interaction in systemic lupus erythematosus

Metabolomic approach with LC-MS reveals significant effect of pressure on diver's plasma

In-vial dual extraction for direct LC-MS analysis of plasma for comprehensive and highly reproducible metabolic fingerprinting

Optimized Analytical Procedures for the Untargeted Metabolomic Profiling of Human Urine and Plasma by Combining Hydrophilic Interaction (HILIC) and Reverse-Phase Liquid Chromatography (RPLC)-Mass Spectrometry

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma, bioRxiv

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum

Prevalence of latent and overt polyautoimmunity in autoimmune thyroid disease: A systematic review and meta-analysis

SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology

Covid-19 and autoimmunity

Prevalence of autoantibody responses in acute coronavirus disease 2019

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Kinetics of viral load and antibody response in relation to COVID-19 severity

Mild versus severe COVID-19: Laboratory

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes, The Lancet Respiratory Medicine

Biomarkers associated with COVID-19 disease progression

The liver in COVID-19: prevalence, patterns, predictors, and impact on outcomes of liver test abnormalities

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Longitudinal analyses reveal immunological misfiring in severe COVID-19

How COVID-19 induces cytokine storm with high mortality

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Sex differences in immune responses that underlie COVID-19 disease outcomes

IL-10 inhibits human T cell proliferation and IL-2 production

T cell responses in patients with COVID-19

Fighting COVID-19 exhausts T cells

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)., Frontiers in Immunology

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

An inflammatory cytokine signature predicts COVID-19 severity and survival

Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality

A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

IL-10: A Multifunctional Cytokine in Viral Infections

Relationship between chest CT manifestations and immune response in COVID-19 patients

High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients

Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and inflammation

Dysregulation of type I interferon responses in COVID-19

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Clinical and immunological features of severe and moderate coronavirus disease 2019

T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

Reappearance of effector T cells is associated with recovery from COVID-19

Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration., medRxiv : The Preprint Server for Health Sciences

We thank Jodi Smith, PhD, from Edanz Group (https://en-authorservices.edanzgroup.com/ac) for editing and reviewing this manuscript for English language.J o u r n a l P r e -p r o o f

C. • Latent autoimmunity and anti-IFN-α antibodies are observed in COVID-19.• COVID-19 CP induces an early but transient effect on antibody and cytokine profile of patients with severe disease • CP decreases activated and effector T cells, and increases memory immune cells.• CP reduces the IL-6/IFN-γ and IL-6/IL-10 ratios.J o u r n a l P r e -p r o o f